FAQ on Clene's Preliminary Data for CNM-Au8(R) in Treating Rett Syndrome

What is CNM-Au8(R)?

CNM-Au8(R) is an investigational first-in-class therapy developed by Clene Nanomedicine Inc., aimed at improving mitochondrial health and neuronal function to treat neurodegenerative diseases.

Why is the preliminary data on CNM-Au8(R) for Rett Syndrome significant?

The data suggests CNM-Au8(R) may treat Rett Syndrome by rescuing mitochondrial dysfunction, offering hope for a severe, rare pediatric neurologic disorder with limited treatment options.

How does CNM-Au8(R) work?

CNM-Au8(R) targets mitochondrial function and the NAD pathway to improve cell survival and function while reducing oxidative stress in the central nervous system.

Who presented the preliminary data on CNM-Au8(R) for Rett Syndrome?

Karen Ho, Ph.D., Clene’s vice president of translational medicine, presented the data at the International Rett Syndrome Foundation 2024 Annual Meeting.

Where can I find more information about Clene and CNM-Au8(R)?

For more information, visit Clene’s official website at www.Clene.com or view the full press release at https://ibn.fm/zLkyd.

What are the current targets of CNM-Au8(R) besides Rett Syndrome?

CNM-Au8(R) is currently being targeted for amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), with potential applications in other neurodegenerative diseases.

When was the preliminary data on CNM-Au8(R) for Rett Syndrome presented?

The data was presented on June 19, 2024, at the International Rett Syndrome Foundation 2024 Annual Meeting in Westminster, Colorado.

What makes CNM-Au8(R) unique?

CNM-Au8(R)’s unique catalytic mechanism and versatility offer potential as a treatment for multiple nervous system diseases, distinguishing it from other therapies.